Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 47
Price : Single User: US $ 3500  US $ 2975 Corporate User: US $ 10500  US $ 8400
This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2016', provides in depth analysis on Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted pipeline therapeutics.

The report provides comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)

  • The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Overview 7
Therapeutics Development 8
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Stage of Development 8
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Therapy Area 9
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Indication 10
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Products Glance 11
Early Stage Products 11
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Companies 12
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Universities/Institutes 14
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 19
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development 21
Alchemia Limited 21
AstraZeneca Plc 22
Carmot Therapeutics Inc 23
Diabetica Limited 24
Eli Lilly and Company 25
Longevity Biotech, Inc 26
Sanofi 27
Zealand Pharma A/S 28
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles 29
AC-163794 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
DAJC-1 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
LBT-6030 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
SAR-438335 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecule to Agonize Gastric Inhibitory Polypeptide for Type 2 Diabetes - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecules to Agonize GLP-1 and GIP Receptors for Type 2 Diabetes and Obesity - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Synthetic Peptide 1 for Type 2 Diabetes and Obesity - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Synthetic Peptide to Agonize GIPR for Alzheimer's Disease - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Synthetic Peptide to Agonize GLP-1 Receptor and GIP Receptor for Diabetes - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Synthetic Peptides to Agonize GLP-1, GIP and Glucagon Receptors for Diabetes and Obesity - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ZPDI-70 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
ZPI-98 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Projects 42
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products 43
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Featured News & Press Releases 44
Sep 15, 2015: Zealand presents new preclinical data on its novel GIP peptide therapeutic, ZP-I-98, at the 51st EASD Annual Meeting 44
Jun 06, 2015: Presentations on ZP-DI-70, novel Zealand preclinical peptide therapeutics as a possible approach for the treatment of Type 2 diabetes and obesity at the American Diabetes Association's (ADA) 74th Scientific Sessions 44
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Alchemia Limited, H2 2016 21
Pipeline by AstraZeneca Plc, H2 2016 22
Pipeline by Carmot Therapeutics Inc, H2 2016 23
Pipeline by Diabetica Limited, H2 2016 24
Pipeline by Eli Lilly and Company, H2 2016 25
Pipeline by Longevity Biotech, Inc, H2 2016 26
Pipeline by Sanofi, H2 2016 27
Pipeline by Zealand Pharma A/S, H2 2016 28
Dormant Projects, H2 2016 42
Discontinued Products, H2 2016 43

List of Figures

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Molecule Types, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 19
  • United States Microfluidics Market Report 2017
    Published: 16-Aug-2017        Price: US 3800 Onwards        Pages: 105
    In this report, the United States Microfluidics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth ra......
  • United States Human Microbiome Market Report 2017
    Published: 15-Aug-2017        Price: US 3800 Onwards        Pages: 101
    In this report, the United States Human Microbiome market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Human M......
  • Global Prepacked Chromatography Columns Market Size, Status and Forecast 2022
    Published: 14-Aug-2017        Price: US 3300 Onwards        Pages: 91
    This report studies the global Prepacked Chromatography Columns market, analyzes and researches the Prepacked Chromatography Columns development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Agilent Technologies - Bio-Rad Laboratories, Inc. - EMD Millipore (Merck KGaA) - GE Healthcare - KNAUER Wissenschaftliche Ger?te GmbH - Pall Corporation (Danah......
  • Global Cell Sorting Market Size, Status and Forecast 2022
    Published: 14-Aug-2017        Price: US 3300 Onwards        Pages: 94
    This report studies the global Cell Sorting market, analyzes and researches the Cell Sorting development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Miltenyi Biotec GmbH? - Affymetrix, Inc. (A Thermo Fisher Scientific Company)? - Sysmex Partec GmbH (A Subsidiary of Sysmex Corporation)? - On-Chip Biotechnologies Co., Ltd.? - Cytonome/St, LLC? - Union Biom......
  • Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022
    Published: 14-Aug-2017        Price: US 5650 Onwards        Pages: 204
    “Global vaccines market projected to grow at a CAGR of 7.5%” The vaccines market is expected to reach USD 49.27 billion by 2022 from USD 34.30 billion in 2017, at a CAGR of 7.5%. Rising prevalence of diseases, increasing government and non government funding for vaccine development, and increasing investments by companies are driving the growth of the vaccines market. On the other hand, market growth may be hindered due to the high cost of vaccine developm......
  • Global Molecular Weight Marker Market Size, Status and Forecast 2022
    Published: 14-Aug-2017        Price: US 3300 Onwards        Pages: 90
    This report studies the global Molecular Weight Marker market, analyzes and researches the Molecular Weight Marker development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Roche - Thermo Fisher Scientific - Agilent Technologies - Sigma-Aldrich - Affymetrix - QIAGEN - Takara Bio - Bio-Rad Laboratories - Promega Corporation......
  • Global Rat Model Market Research Report 2017
    Published: 14-Aug-2017        Price: US 2900 Onwards        Pages: 106
    In this report, the global Rat Model market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Rat Model in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan - ......
  • United States Laser Capture Microdissection Market by Manufacturers, States, Type and Application, Forecast to 2022
    Published: 14-Aug-2017        Price: US 4480 Onwards        Pages: 122
    Laser Capture Microdissection (LCM) technology is a contagion free process for obtaining sub-populations of tissue cells under direct microscopic apparition. In addition, laser-capture Microdissection technology isolates specific cells by dissecting unwanted cells. Laser Capture Microdissection technology harvests the cells of attention straight to give pure enriched cells. This technology helps in preserving the genuine morphology of the dissected cell or tissue sample. The Laser Capture Microd......
  • Global Prepacked Chromatography Columns Market Research Report 2017
    Published: 14-Aug-2017        Price: US 2900 Onwards        Pages: 104
    In this report, the global Prepacked Chromatography Columns market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Prepacked Chromatography Columns in these regions, from 2012 to 2022 (forecast), covering - North America - ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs